


Editorial Policy

In keeping with its corporate commitment to “Otsuka-people creating new products for better health worldwide,” the Otsuka Group endeavors to create new and innovative products in diverse areas related to health, as a global healthcare company devoted to better health worldwide.

The Otsuka Group CSR Report provides an overview of the diverse initiatives that the Otsuka Group engages in: from its relationship with stakeholders in the course of doing business to realizing its corporate commitment. We hope that this report promotes a better mutual understanding with our stakeholders.

In this report, we focus on the three concepts below in addressing the five areas of CSR at the Otsuka Group — health, environment, quality, culture and employees.



Priority initiatives Here are the activities that the Otsuka Group is currently focused on.

Scope of report

This report focuses on Otsuka Holdings and encompasses information for Otsuka Group companies worldwide, centering on the following 13 Group companies in Japan:

Otsuka Pharmaceutical Co., Ltd.	Otsuka Foods Co., Ltd.	Okayama Taiho Pharmaceutical Co., Ltd.
Otsuka Pharmaceutical Factory, Inc.	EN Otsuka Pharmaceutical Co., Ltd.	Otsuka Packaging Industries Co., Ltd.
Taiho Pharmaceutical Co., Ltd.	Otsuka Electronics Co., Ltd.	JIMRO Co., Ltd.
Otsuka Warehouse Co., Ltd.	Otsuka Techno Corporation	
Otsuka Chemical Co., Ltd.	J.O. Pharma Co., Ltd.	

Period covered

Due to a change in the fiscal year-end to December, the results cover the period from April 1, 2014 to December 31, 2014. The activities reported on include some conducted more recently.

Publication schedule

The next report is scheduled for publication in summer 2016.

Guidelines referenced


This report was compiled with reference to the GRI Sustainability Reporting Guidelines 3rd Edition, ISO 26000, and the Environmental Report Guidelines 2012 Edition issued by Japan’s Ministry of the Environment.

Corporate Profile


As of December 31, 2014

Company name: Otsuka Holdings Co., Ltd.
Established: July 8, 2008
Capital: JPY 81,690 million
Head Office: 2-9 Kanda-Tsukasamachi, Chiyoda-ku, Tokyo 101-0048, Japan
Tokyo Headquarters: Shinagawa Grand Central Tower, 2-16-4 Konan, Minato-ku, Tokyo 108-8241, Japan
Representative: Tatsuo Higuchi, President and CEO
Employees: 73 (Consolidated: 29,482)
Scope of consolidation: 102 consolidated subsidiaries and 17 equity-method affiliates
Business description: Control, management, and other operational aspects of business activities related to holding the shares of companies that operate in the fields of pharmaceuticals, nutraceuticals, consumer products, and other businesses.


Consolidated Net Sales




Consolidated Operating Income



Consolidated Ordinary Income




Research and Development Expenses




Consolidated Net Sales by Geographical Segment (FY2014*)

Sales to customers by market



Consolidated Net Sales by Business Segment (FY2014*)

Sales to customers by market



* Due to a change in the fiscal year-end to December, FY2014 covers the nine-month period from April 1, 2014 to December 31, 2014.

Contents

About the Otsuka Group	2
Corporate Profile	2
Otsuka Group Across the Globe	3
Business Overview of the Otsuka Group	5
CSR Highlights	7
Message from the President	9
Message from the President	9
Corporate Philosophy	11
Health	12
Addressing Unmet Needs	13
Advocating the Importance of Hydration and Electrolytes	15
Nutrition Education	16
Communicating Health Information	17
Environment	18
Eco-Friendly Plants	19
Environmental Management	21
Environmental Performance Data	22
Eco-Friendly Products	25
Low Carbon Neutral Initiatives	27
Initiatives for a Resource Recycling Society	29
Quality	30
Safety Initiatives	31
Corporate Governance	33
Compliance	34
Risk Management	35
Culture	36
Community Initiatives	37
Cleanup Activities	39
Community Exchange	40
Youth Education	41
Employees	42
Diversity	43
Work-Life Balance	45
Development of Human Capital	46
Employee Health	47
Third-Party Opinion/ Editorial Postscript	48